TrialSignal
Clinical trial intelligence report
A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00193245
Status
COMPLETED
Phase
PHASE2
Sponsor
SCRI Development Innovations, LLC
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the efficacy and toxicity of oral topotecan compared to intravenous docetaxel in patients with relapsed or progressive non-small cell lung cancer. Conducted by SCRI Development Innovations, LLC, the study involved 80 participants and aimed to determine overall response rates and secondary outcomes such as time to progression and overall survival.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00193245
Indication
Lung Cancer
Modality
small molecule
Target
Non-Small Cell Lung Cancer
Intervention
Topotecan, Docetaxel
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.